valopicitabine + peginterferon alfa-2b

A combination investigational therapy for chronic hepatitis C virus (HCV) infection, specifically genotype 1, composed of valopicitabine (NM283), an oral small molecule prodrug of 2'-C-methylcytidine that inhibits HCV RNA polymerase (NS5B), and peginterferon alfa-2b, a recombinant, pegylated interferon that stimulates the innate antiviral immune response via activation of the type 1 interferon receptor and subsequent JAK/STAT signaling. The combination was developed as an alternative for patients not responding to standard therapies, aiming to improve sustained virological response rates in both treatment-naive and treatment-experienced populations. Clinical trials showed marked reductions in viral load and a notable percentage of patients achieving undetectable HCV RNA, though some trials suggested efficacy was not superior to standard of care and ribavirin was absent in combination arms[1][3][5].

Brand names

PEG-Intron

Other names

valopicitabine + pegylated interferonNM283 + peginterferon alfa-2b